New combo therapy aims to control advanced prostate cancer

NCT ID NCT06894511

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a hormone therapy to a targeted radiation drug (lutetium-177) is safe and effective for men with a certain type of advanced prostate cancer that has spread and stopped responding to hormone therapy alone. About 7 participants will receive either the combination or the radiation drug alone. The goal is to control the disease, not cure it, as ongoing treatment is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Locations

Arizona Center for Cancer Care

Gilbert, Arizona, 85297, United States
Cancer And Blood Spclsts of AZ

Casa Grande, Arizona, 85122, United States
Cancer Specialists of North Florida

Jacksonville, Florida, 32256, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Urology Cancer Center PC

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.